4Harenberg J.Development of new anticoagulants:present and future[J].Semin Thromb Haemost,2008,34(8):779-793.
5Harenberg J,Wehling M.Current and future prospects foR.anticoagulant therapy:inhibitors of factoR.Ⅹa and factoR.Ⅱa[J].Semin Thromb Haemost,2008,34(1):39-57.
6Weitz J I,Hirsh J,Samama M M.New antithrombotic drugs:american college of chest physicians evidence-based clinical practice guidelines (8th ed)[J].Chest,2008,133(6):234-256.
7Spyropoulos A C.Investigational treatments of venous thromboembolism[J].Expert Opin Investig Drugs,2007,16(4):431-440.
8BulleR.H R,Cohen A T,Davidson B,et al.Extended prophylaxis of venous thromboembolism with idraparinux[J].N Engl J Med,2007,357(11):1105-1112.
9BulleR.H R,Cohen A T,Davidson B,et al.Idraparinux versus standard therapy foR.venous thromboembolic disease[J].N Engl J Med,2007,357(11):1094-1104.
10BousseR.M G,BouthieR.J,BülleR.H R,et al.Comparison of idraparinux with vitamin K antagonists foR.prevention of thromboembolism in patients with atrial fibrillation:a randomised,open-label,non-inferiority trial[J].Lancet,2008,371(9609):315-321.
二级参考文献52
1Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy [ J ]. Chest, 2004, 126(3 Suppl) :338S- 400S.
2Ansell J, IAirsh J, Poller L, et al. The pharmacology and management of the vitamin K antagonists: the Seventh AC- CP Conference on Antithrombotic and Thrombolytic Therapy[J]. Chest, 2004,126(3 Suppl) :204S- 233S.
3Shimizu T, Nishihira J, Watanabe H, et al. Macrophage migration inhibitory factor is induced by thrombin and factor Xa in endothelial cells[ J]. J Biol Chem, 2004, 279 (14) : 13729 - 13737.
4Vesey DA, Cheung CW, Kruger WA, et al. Thrombin stimulates proinflammatory and proliferative responses in primary cultures of human proximal tubule cells[J]. Kidney Int, 2005,67(4):1315- 1329.
5Tarzami ST, Wang G, Li W, et al. Thrombin and PAR-1 stimulate differentiation of bone marrow-derived endothelial progenitor cells[J]. J Thromb Haemost, 2006,4(3):656 - 663.
6Bauer KA. New anticoagulants: anti IIavs anti Xa-is one better [J ] ? J Thromb Thrombolysis, 2006,21 ( 1 ) :67 - 72.
7Hermans C, Claeys D. Review of the rebound phenomenon in new anticoagulant treatments [ J]. Curt Med Res Opin, 2006,22(3) :471 - 481.
8Turpie AG, Baue, KA, Eriksson BI, et al. Fondaparinux vs enoxaparin for the prevention of venous thromboembolism in major orthopedic surgery: a meta-analysis of 4 randomized double-blind studies [ J]. Arch Intern Med, 2002, 162(16) : 1833 - 1840.
9Samama MM, Gerotziaf:as GT, Elalamy I, et al. Biochemistry and clinical pharmcology of new anticoagulant agents [ J ]. Pathophysiol Haemost Thromb, 2002, 32 (5/ 6) :218 - 224.
10Perzborn E, Strassburger J, Wilmen A, et al. In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939-an oral, direct Factor Xa inhibitor[J]. J Thromb Haemost, 2005,3 ( 3 ) : 514 - 521.
